Join our mailing list and receive the monthly BioVox newsletter for free!

RELATED ARTICLES
Better and cheaper treatment of Crohn’s disease: BIOCYCLE

Crohn’s disease is a type of inflammatory bowel disease, which is becoming increasingly prevalent in the developing world. It’s an immune-related …


TiGenix inks massive deal with Takeda

Today cell therapy specialist TiGenix has disclosed a new deal with the Japanese pharmaceutical giant Takeda. The agreement allows Takeda the righ…


Galapagos finally managed to close long awaited deal

Earlier this year, AbbVie turned down its deal with Galapagos for co-development and commercializiation of the drug filgotinib for treatment of re…

POPULAR TAGS

Tigenix' cash position gets stronger and stronger

Written by DS on in the category news with the tags , .


Tigenix received in July a contribution of 25 million euros from Takeda, which doubled its cash position. The Japanese company wants to market Cx601, Tigenix' flagship product.

Cx601 is a treatment for peri-anal fistula in patients with Crohn's disease. It is not a drug but an injection of stem cells. As the treatment proved effective, Takeda bought the rights.

When the European drug authorities will approve Cx601, which most likely will be in the second half of 2017, Tigenix will receive 15 million euros more. Moreover, depending on the sales, Tigenix could receive up to 340 million euros in royalties.

Read more about Tigenix.

"With our recent licensing agreement with Takeda, which has a solid track record and is a strong leader in gastroenterology, we have the best partner and resources to succesfully commercialize Cx601. We also have acquired the financial strength to continue the clinical development of Cx106 in the United States," says Eduardo Bravo, the Spanish CEO of TiGenix.

As Tigenix retained the US rights, it can possibly still acquire 50 percent of the global income of Cx601.

 

Read more about: , .

RELATED ARTICLES
Better and cheaper treatment of Crohn’s disease: BIOCYCLE

Crohn’s disease is a type of inflammatory bowel disease, which is becoming increasingly prevalent in the developing world. It’s an immune-related …


TiGenix inks massive deal with Takeda

Today cell therapy specialist TiGenix has disclosed a new deal with the Japanese pharmaceutical giant Takeda. The agreement allows Takeda the righ…


Galapagos finally managed to close long awaited deal

Earlier this year, AbbVie turned down its deal with Galapagos for co-development and commercializiation of the drug filgotinib for treatment of re…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Flanders.bio GSK Janssen XpandInnovation UGent Itera Life Science KU Leuven V-Bio Ventures Biowin Turnstone

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.